Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com
COLUMBIA, Md. and TORONTO, Sept. 29, 2015 /PRNewswire/ -- Medifocus, Inc. (OTCQX: MDFZF andTSXV: MFS) ("Medifocus" or the "Company"), a biotechnology company with a portfolio of medical technologies that utilizes heat-activation to treat conditions ranging from urological problems to breast cancer treatment and extends to gene therapy, announced today that Dr. Augustine Y. Cheung, PhD, President and CEO), will present live at VirtualInvestorConferences.com on October 1, 2015.
DATE: Thursday, October 1, 2015
TIME: 10:45AM ET
This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as the association's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.
It is recommended that investors pre-register to save time and receive event updates.
Recent Company Highlights
- On June 16th, 2015, the Company appointed Christopher Kaplan as a member of the its recently formed Strategic Advisory Board (SAB). Mr. Kaplan has an exceptional background of both domestic and international experience and is well-positioned to support Medifocus as they transition into a biotechnology company
- On May 27th, 2015, the Company announced that it has entered into an option agreement with Duke University regarding heat-activated and tumor targeted Immunotherapy. The two parties are actively negotiating an exclusive license to the Patent Rights of a Duke invention for the development of heat-activated and tumor targeted Immunotherapy for treatment of cancer and other diseases
Learn more about the event: www.virtualinvestorconferences.com
About Medifocus, Inc.
Medifocus, Inc. (TSXV-MFS, OTC-MDFZF) is biotechnology company with a portfolio of medical technologies that utilize head-activation to treat conditions ranging from urological problems to breast cancer treatment and extends to gene therapy. Heat is known to accelerate numerous chemical and biochemical reactions, and Medifocus' portfolio relies on this fact to improve treatment of patients. Its Prolieve® Thermodilatation System offers relief from Benign Prostatic Hyperplasia (BPH) to millions of men with a simple, 45-minute, in-office treatment. Its APA 1000 Breast Cancer Treatment System is currently in phase 3 clinical trials, and it is designed to destroy localized breast tumors through the application of heat alone or in combination with chemotherapy. Medifocus has recently signed an agreement with Duke University to negotiate an exclusive license related to a "method for selective expression of therapeutic genes in cancer cells by hyperthermia." This is a novel approach to control gene expression with focused heat and is a unique method to achieve precise viral delivery of gene therapy and molecular therapeutics on demand. Medifocus will work on further development of the delivery vector, making it universal to accommodate other molecular and genetic therapeutics. The Company believes this could result in an entire stable of gene-specific, heat-activated treatments for a variety of medical conditions.
For more details, please visit:
About OTC Markets Group Inc.
OTC Markets Group Inc. operates Open, Transparent and Connected financial markets for 10,000 U.S. and global securities. Through our OTC Link® ATS, we directly link a diverse network of broker-dealers that provide liquidity and execution services for a wide spectrum of securities. We organize these securities into markets to inform investors of opportunities and risks: the OTCQX® Best Market; the OTCQB® Venture Market; and the OTC Pink® Open Market. Our data-driven platform enables investors to easily trade through the broker of their choice at the best possible price and empowers a broad range of companies to improve the quality and availability of information for their investors. To learn more about how we create better informed and more efficient financial markets, visit www.otcmarkets.com.
OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS.
VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PR Newswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.
Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.
This news release contains "forward-looking statements" and "forward-looking information", which may not be based on historical facts. Forward-looking statements and forward-looking information, include, but are not limited to, information and statements with respect to the benefit to Medifocus' future growth resulting from the acquisition of additional intellectual property rights, additional treatment possibilities and the expectation that sales from Prolieve® may accelerate as a consequence. Forward-looking statements are frequently characterized by words such as "plan," "expect," "project," "intend," "believe," "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made. Such forward-looking statements and forward-looking information involve known and unknown risks, uncertainties and other factors that may cause the actual results events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or forward-looking information. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements and forward-looking information. Except as required by applicable securities laws, the Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements or forward-looking information contained herein to reflect future results, events or developments.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Medifocus, Inc.
For further information: Medifocus, Inc. Company Relations: John Mon, COO, Tel: 410-290-5734, email@example.com; Medifocus, Inc. Investor Relations: Michael Porter, President, Porter, LeVay and Rose, Tel: 212-564-4700, Mike@plrinvest.com; OTC Markets Group Inc., Saskia Sidenfaden, +1 (212) 896-4428, firstname.lastname@example.org; VirtualInvestorConferences.com, Bradley H. Smith, Director of Marketing, IR and Compliance Services, PR Newswire, +1.201.947.7157, email@example.com, http://www.medifocusinc.com